B
CGEM icon

Bailard’s Cullinan Oncology CGEM Stock Holding History

Bailard’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,800
Closed -$110K – 744
2023
Q4 		$110K Buy
+10,800
New +$95.7K ﹤0.01% 686
2023
Q2 		– Sell
-11,000
Closed -$113K – 701
2023
Q1 		$113K Buy
+11,000
New +$121K ﹤0.01% 680
2021
Q4 		– Sell
-9,600
Closed -$217K – 729
2021
Q3 		$217K Buy
+9,600
New +$257K 0.01% 647

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Bailard's CGEM Position: Q1 2024 in Review

Bailard sold out of Cullinan Oncology (CGEM) in Q1 2024, closing a stake of 10,800 shares — an estimated $110K sold.

Bailard first reported a position in CGEM in Q3 2021 and held it in 3 quarters. The position peaked at $217K in Q3 2021. 113 funds tracked by Wall St. Rank hold CGEM as of Q1 2024.

  • Bailard reported no remaining Cullinan Oncology position as of Q1 2024 after selling out during the quarter.
  • Bailard sold 10,800 Cullinan Oncology shares in Q1 2024, an estimated $110K.
  • Bailard first reported a position in Cullinan Oncology in Q3 2021 and held it in 3 quarters.
  • Bailard's Cullinan Oncology position peaked at $217K in Q3 2021.
  • 113 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2024.

Based on Bailard's 13F filing for Q1 2024, filed 8 May 2024.